HIGHLIGHTS
- who: Baswanth Oruganti from the (UNIVERSITY) have published the paper: Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib, in the Journal: (JOURNAL) of January/24,/2022
- what: The authors explore the effectiveness of combination therapies of the recently developed allosteric inhibitor asciminib with the ATP-competitive inhibitors nilotinib and dasatinib in inhibiting the BCR-Abl1 kinase activity in CML cell lines. Through these experiments, the authors demonstrate that asciminib significantly enhances the inhibition activity of nilotinib, but not of dasatinib. In view of these encouraging findings on the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.